Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01718821

Enrollment

Registered

2012-10-31

Start date

2012-09-30

Completion date

2014-09-30

Last updated

2014-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Neuropathic Pain, Pain, Quality of Life, Upper GI Cancer

Brief summary

Pain is one of the most common symptoms associated with cancer. The approach to pain management compresses routine pain assessments, utilizes both pharmacologic and nonpharmacologic interventions, and requires ongoing reevaluation of the patient. Cancer pain can be well controlled in the vast majority of patients if the algorithms of pain control are systematically applied, carefully monitored, and tailored to the needs of the individual patient.This study is aimed to assess the current pain managements in upper gastrointestinal cancer patients in Taiwan. The effects of neuropathic pain and depression on the enrolled patients would also be assessed.

Interventions

None listed

Study design

Observational model

ECOLOGIC_OR_COMMUNITY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* with a diagnose of advanced upper GI cancer based on pathology or imaging studies * could report pain intensities and answer questionnaires by him/herself

Exclusion criteria

* with major neurologic or psychiatric diseases * could not report pain intensities and answer questionnaires by him/herself

Design outcomes

Primary

Measure	Time frame	Description
Pain, assessed by BPI-SF.	Assessed at enrolled date (Day 1)	Pain intensities of participants would be assessed by BPI-SF at D1.
Changes in pain, assessed by BPI-SF.	Baseline and 1 month.	Changes in pain intensities of participants would be assessed by BPI-SF. The changes in pain would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.

Secondary

Measure	Time frame	Description
Quality of life, assessed by EROTC QLQ C30.	Day 1	Quality of life of participants would be assessed by questionnaires as mentioned at D1.
Neuropathic pain, assessed by DN4 questions.	Day 1	Neuropathic pain of participants would be assessed by questionnaires as mentioned at D1.
Depression, assessed by two stem questions.	Assessed at enrolled date (Day 1)	Depression of participants would be assessed by questionnaires as mentioned at D1.
Changes in neuropathic pain. Neuropathic pain, assessed by DN4 questions.	Baseline and 1 month.	Changes in neuropathic pain would be assessed by questionnaires as mentioned. The changes would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.
Changes in quality of life. Quality of life, assessed by EROTC QLQ C30.	Baseline and 1 month.	Changes in quality of life would be assessed by questionnaires as mentioned. The changes would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.
Changes in depression, assessed by two stem questions.	Baseline and 1 month.	Changes in depression status would be assessed by questionnaires as mentioned. The changes would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.

Countries

Taiwan

Outcome results